

**MORRISON & FOERSTER LLP FAX RECEIVED**

Attorneys at Law  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5100  
Facsimile: (858) 720-5125

APR 10 2002

**GROUP 1600  
OFFICIAL**

To: <No Name>  
U.S. Patent and Trademark Office

Facsimile: 1-703-308-4556 (TC1600)

From: Kate H. Murashige

Date: April 9, 2002

We are transmitting a total of 17 pages (including this page).  
Original or hard copy to follow if this box is checked ☐.

Preparer of this slip has confirmed that facsimile number given is correct: 9111/TMP

This facsimile contains confidential information which may also be privileged. Unless you are the addressee (or authorized to receive for the addressee), you may not copy, use, or distribute it. If you have received it in error, please advise Morrison & Foerster LLP immediately by telephone or facsimile and return it promptly by mail.

Comments: Serial No. 09/972,582  
Our reference: 21900-20284.02



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
 Washington, D.C. 20231  
 www.uspto.gov

Application Number	Filing Date	First Named Applicant	Atty. Docket No.
09/972,582	10/05/2001	Chakravarty, Sarvajit	219002028402

25225 *KHM*  
 MORRISON & FOERSTER LLP  
 3811 VALLEY CENTRE DRIVE  
 SUITE 500  
 SAN DIEGO CA 92130-2332

Title: Qinzoline derivatives as medicaments

Date Mailed: 03/19/2002

## Request for Substitute Papers

The papers filed on 01/24/02 (certificate of mailing dated 01/07/02) are no longer in condition to become part of the permanent records of the United States Patent and Trademark Office (USPTO) for this application (37 CFR 1.52(a)) due to the United States Postal Service sanitization process.

The USPTO requests that applicant provide a copy of the above-identified papers (except for any U.S. or foreign patent documents submitted with the above-identified papers) with a statement that such copy is a complete and accurate copy of the above-identified papers (signing and returning a copy of this notice will provide such a statement). The reply to this letter should be submitted to the USPTO by facsimile at the number indicated.

Alternatively, the reply to this letter may be hand-carried to the Customer Service Window located in Room 1B03 of Crystal Plaza Building 2, Arlington, Virginia, 22202.

The USPTO **strongly** prefers that the reply to this letter be submitted by facsimile. However, if applicant cannot submit the reply to this letter by facsimile (or hand-delivery), the reply may be mailed to: Box Duplicate, U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202-2327.

This letter is not a notice under 37 CFR 1.251. However, failure to timely replay to this notice within **two (2) weeks** of the date of receipt of this letter may result in the USPTO issuing a notice under 37 CFR 1.251. A copy of this notice should be included with the reply.

DOCKETED *Resp Due*

REMINDER: *4/3/02*

DUE DATE: \_\_\_\_\_

The enclosed papers are a complete and accurate copy of the above-identified papers.

Name: Kate H. Murashige Registration No.: 29,959 FINAL DUE DATE: \_\_\_\_\_

Signature: *Kate H. Murashige* Date: April 9, 2002

**RECEIVED**

**MAR 26 2002**

MORRISON & FOERSTER  
 SAN DIEGO

COPY

Docket No.: 219002028402	Att'y: Kate H. Murashige <i>SB</i>
Serial No.: 09/972,582	Filing Date: 5 October 20001
Title: QUINAZOLINE DERIVATIVES AS MEDICAMENTS	
Date of Mailing: 7 January 2002	

**Papers enclosed:**

1. Transmittal (1 page)
2. Submission of Substitute Formal Drawings (1 page)
3. Copy of Notice To File Corrected Application Papers (1 page)
4. Substitute Drawings (10 sheets)
5. Return postcard

RECEIVED BY THE UNITED STATES PATENT AND TRADEMARK OFFICE



**MORRISON & FOERSTER LLP  
3811 VALLEY CENTRE DRIVE  
SUITE 500  
SAN DIEGO, CA 92130-2332**

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → **+**Approved for use through 10/31/02. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number Of Pages In This Submission

13

Application Number	09/872,582
Filing Date	5 October 2001
First Named Inventor	Sarvajit CHAKRAVARTY, et al.
Group Art Unit	1624
Examiner Name	Not yet assigned
Attorney Docket No.	219002028402

**ENCLOSURES (check all that apply)**

- |  |  |  |
|--|--|--|
| <input type="checkbox"/> Fee Transmittal Form                                      | <input type="checkbox"/> Assignment Papers   | <input type="checkbox"/> After Allowance Communication to Group                            |
| <input type="checkbox"/> Fee Attached  | <input checked="" type="checkbox"/> Drawing(s)   | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences        |
| <input type="checkbox"/> Amendment / Reply   | <input type="checkbox"/> Licensing-related Papers  | <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final   | <input type="checkbox"/> Petition  | <input type="checkbox"/> Proprietary Information   |
| <input type="checkbox"/> Affidavits/declarations                                   | <input type="checkbox"/> Petition to Convert to a Provisional Application                  | <input type="checkbox"/> Status Letter   |
| <input type="checkbox"/> Extension of Time Request                                 | <input type="checkbox"/> Power of Attorney, Revocation<br>Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):            |
| <input type="checkbox"/> Express Abandonment Request                               | <input type="checkbox"/> Terminal Disclaimer   | <input type="checkbox"/> Return Postcard   |
| <input type="checkbox"/> Information Disclosure Statement                          | <input type="checkbox"/> Request for Refund  | <input type="checkbox"/> Copy of Notice to File Corrected Application Papers               |
| <input type="checkbox"/> Certified Copy of Priority Document(s)                    | <input type="checkbox"/> CD, Number of CD(s) _____   |  |
| <input type="checkbox"/> Response to Missing Parts/<br>Incomplete Application      | Remarks  |  |
| <input type="checkbox"/> Response to Missing Parts<br>under 37 CFR 1.52 or 1.53(b) |  |  |

**SIGNATURE OF APPLICANT, ATTORNEY OR AGENT**

Firm or Individual Name	Kate H. Murashige, Registration No. 29,959 3811 Valley Centre Drive, Suite 500 San Diego, CA 92130 Morrison & Foerster LLP
Signature	<i>Kate H. Murashige</i>
Date	January 7, 2002

**CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on January 7, 2002.

Tami M. Procopio

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

sd-72970

PATENT  
Docket No. 219002028402

## CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on January 7, 2002.

  
Tami M. Procopio

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Sarvajit CHAKRAVARTY, et al.

Serial No.: 09/972,582

Filing Date: 5 October 2001

For: QUINAZOLINE DERIVATIVES AS  
MEDICAMENTS

Examiner: To Be Assigned

Group Art Unit: 1624

## SUBMISSION OF SUBSTITUTE FORMAL DRAWINGS

Assistant Commissioner for Patents  
Washington, D.C. 20231


Dear Sir:

In complete response to the Notice to File Corrected Application Papers Under  
37 C.F.R. § 1.84 dated 6 November 2001, attached please find 10 sheet(s) of substitute formal  
drawings in connection with the above-identified application.

Respectfully submitted,

Dated: 7 January 2002

By:

  
Kate H. Murashige  
Registration No. 29,959Morrison & Foerster LLP  
3811 Valley Centre Drive, Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5112  
Facsimile: (858) 720-5125

sd-72978



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/972,582	10/05/2001	Sarvajit Chakravarty	219002028402

25225  
MORRISON & FOERSTER LLP  
3811 VALLEY CENTRE DRIVE  
SUITE 500  
SAN DIEGO, CA 92130-2332

CONFIRMATION NO. 4932  
FORMALITIES LETTER

\*0000000007028273\*

Date Mailed: 11/06/2001

**NOTICE TO FILE CORRECTED APPLICATION PAPERS**

**Filing Date Granted**

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- **Substitute drawings in compliance with 37 CFR 1.84 because:**
  - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. ( 5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);

***A copy of this notice MUST be returned with the reply.***

Customer Service Center  
Initial Patent Examination Division (703) 508-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

\*\* TOTAL PAGE.17 \*\*

04/09/02 TUE 17:08 [TX/RX NO 6560] 017